On the upside
Keryx Biopharmaceuticals (Nasdaq: KERX) reached a Special Protocol Assessment agreement with the Food and Drug Administration regarding the design of a Phase 3 trial for its end-stage renal disease treatment Zerenex.
On Track Innovations (Nasdaq: OTIV) landed contracts for a national eID program valued at over $30 million.
Goldman Sachs upgraded Tenet Healthcare (NYSE: THC) and placed the company on its conviction buy list citing the hospital operator's valuation.
On the downside
Brightpoint (Nasdaq: CELL) disappointed with a fourth quarter guidance below expectations.
Barclays cited lower mortgage volumes for downgrading Fidelity National Financial (NYSE: FNF).
In the broad market, declining issues outpaced advancers by a margin of nearly 5 to 4 on the NYSE and by more than 5 to 3 on Nasdaq. The Russell 2000 which tracks small cap stocks slipped 3 points to 636.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here